82 related articles for article (PubMed ID: 2404626)
1. Effects of a vasopressin antagonist with combined antipressor and antiantidiuretic activities in rats with left ventricular dysfunction.
Mulinari RA; Gavras I; Wang YX; Franco R; Gavras H
Circulation; 1990 Jan; 81(1):308-11. PubMed ID: 2404626
[TBL] [Abstract][Full Text] [Related]
2. Effects of chronic administration of a vasopressin antagonist with combined antivasopressor and antiantidiuretic activities in rats with left ventricular dysfunction.
Wang YX; Franco R; Gavras I; Gavras H
J Lab Clin Med; 1991 Apr; 117(4):313-8. PubMed ID: 1826304
[TBL] [Abstract][Full Text] [Related]
3. Effect of vasopressin antagonist d(CH2)5Tyr(Et)VAVP on plasma arginine vasopressin level after osmotic stimulus.
László FA; Laczi F; Janáky T; Baláspiri L
Endocr Regul; 1991 Sep; 25(3):181-3. PubMed ID: 1764609
[TBL] [Abstract][Full Text] [Related]
4. A specific antagonist of vasopressin produced plasma hyperosmolality and reduced ischemic-induced cerebral edema in rats.
Tang AH; Ho PM
Life Sci; 1988; 43(5):399-403. PubMed ID: 3398706
[TBL] [Abstract][Full Text] [Related]
5. Vasopressin antagonism in the squirrel monkey (Saimiri sciureus).
Kinter LB; Churchill S; Stassen FL; Moore M; Huffman W
J Pharmacol Exp Ther; 1987 Jun; 241(3):797-803. PubMed ID: 3598903
[TBL] [Abstract][Full Text] [Related]
6. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
[TBL] [Abstract][Full Text] [Related]
7. Effect of the vasopressin antagonist d(CH2)5 Tyr(Et)VAVP on diuresis in rat.
László FA; Csáti S; Baláspiri L; Manning M
Acta Med Hung; 1984; 41(1):65-73. PubMed ID: 6739224
[TBL] [Abstract][Full Text] [Related]
8. Clinical studies with a vascular vasopressin antagonist.
Waeber B; Nussberger J; Hofbauer KG; Nicod P; Brunner HR
J Cardiovasc Pharmacol; 1986; 8 Suppl 7():S111-6. PubMed ID: 2434764
[TBL] [Abstract][Full Text] [Related]
9. Vasopressin and angiotensin II contribute equally to the increased afterload in rabbits with heart failure.
Arnolda L; McGrath BP; Johnston CI
Cardiovasc Res; 1991 Jan; 25(1):68-72. PubMed ID: 2054832
[TBL] [Abstract][Full Text] [Related]
10. Discovery and therapeutic utility of vasopressin antagonists in rats.
Kinter LB; Dytko G; Ashton D; McDonald J; Huffman W; Stassen F
J Cardiovasc Pharmacol; 1986; 8 Suppl 7():S36-43. PubMed ID: 2434770
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the pharmacologic properties of a vasopressin antagonist in Brattleboro rats.
Mah SC; Hofbauer KG
J Pharmacol Exp Ther; 1988 Jun; 245(3):1028-32. PubMed ID: 2968448
[TBL] [Abstract][Full Text] [Related]
12. Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction.
Wada K; Tahara A; Arai Y; Aoki M; Tomura Y; Tsukada J; Yatsu T
Eur J Pharmacol; 2002 Aug; 450(2):169-77. PubMed ID: 12206855
[TBL] [Abstract][Full Text] [Related]
13. Effect of the vasopressin antagonist d/CH2/5Tyr/Et/VAVP on the antidiuretic action of exogenous and endogenous vasopressin.
László FA; Csáti S; Baláspiri L
Acta Endocrinol (Copenh); 1984 May; 106(1):52-5. PubMed ID: 6730854
[TBL] [Abstract][Full Text] [Related]
14. Short-term hemodynamic effects of vasopressin V1-receptor inhibition in chronic right-sided congestive heart failure.
Stone CK; Liang CS; Imai N; Sakamoto S; Sladek CD; Hood WB
Circulation; 1988 Nov; 78(5 Pt 1):1251-9. PubMed ID: 3180381
[TBL] [Abstract][Full Text] [Related]
15. Effect of arginine vasopressin antagonist on renal water excretion in glucocorticoid and mineralocorticoid deficient rats.
Ishikawa S; Schrier RW
Kidney Int; 1982 Dec; 22(6):587-93. PubMed ID: 7162034
[No Abstract] [Full Text] [Related]
16. Selective vasopressin inhibition in rats with heart failure decreases afterload and results in venodilatation.
Raya TE; Gay RG; Goldman S
J Pharmacol Exp Ther; 1990 Dec; 255(3):1015-20. PubMed ID: 2262890
[TBL] [Abstract][Full Text] [Related]
17. [Hemodynamic effects of an inhibitor of the vascular effects of vasopressin in patients with congestive heart failure].
Nicod P; Goy J; Waeber B; Bussien JP; Turini GA; Nussberger J; Hofbauer KG; Brunner HR
Schweiz Med Wochenschr; 1985 Dec; 115(50):1823-5. PubMed ID: 3841412
[TBL] [Abstract][Full Text] [Related]
18. Biological activities of some new arginine vasopressin analogues containing unusual amino acids.
Varga C; Somlai C; Baláspiri L; László FA
Acta Physiol Hung; 1993; 81(2):183-92. PubMed ID: 8197874
[TBL] [Abstract][Full Text] [Related]
19. Effect of the aquaretic vasopressin antagonists d(CH2)5[D-Tyr(Et)2-Val4]AVP and d(CH2)5[D-Phe2-Phe4]AVP on urine production in healthy dogs.
van Oosterhout IC; Rijnberk A; Mol JA
Horm Metab Res; 1992 May; 24(5):244-5. PubMed ID: 1398466
[No Abstract] [Full Text] [Related]
20. Role of endothelin and vasopressin in DOCA-salt hypertension.
Yu M; Gopalakrishnan V; McNeill JR
Br J Pharmacol; 2001 Apr; 132(7):1447-54. PubMed ID: 11264238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
